DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks
This article was originally published in The Pink Sheet Daily
Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.
You may also be interested in...
WASHINGTON - U.S. FDA issued a warning letter to Eisai for "serious" violations regarding a Dacogen (decitabine) marketing document that minimize risk and "greatly overstates the efficacy of Dacogen.
Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."
FDA is harnessing established science on human cognition to assess whether a device or drug maker's advertisement is misleading, according to a May 27 draft 1guidance document from the agency